9926:HKEXAkeso, Inc. Analysis

Akeso, Inc. (9926.HK) is trading at HK$92, well below its 20‑day SMA of HK$106 and near the 52‑week low support of HK$82.85, while technicals show an RSI of 31.9 (oversold) and a bearish MACD divergence. The stock is highly volatile (30‑day volatility >56%) and carries a beta of 1.15, indicating amplified market moves. On the fundamentals side, revenue surged 49.6% YoY with a strong gross margin of 77%, yet operating and net margins remain deeply negative, cash flow is negative, and the forward PE of 42.6 dwarfs the industry average of 24.8, suggesting a premium valuation. Recent material news highlights that Akeso will present compelling Phase II data for its AK117 CD47 antibody at the EHA Congress and showcase over 40 oncology studies at ASCO 2026, which could act as catalysts if outcomes are positive.
Given the mix of a distressed balance sheet, sizable cash reserves, and a pipeline that could unlock future revenue, the near‑term outlook is cautious pending trial read‑outs, while the medium‑term upside hinges on successful commercialization of its bi‑specific antibodies. Investors should weigh the high volatility and regulatory uncertainties against the potential for breakthrough approvals.